Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,580.70 +125.86 1.01%
S&P 500 1,332.42 +14.60 1.11%
Nasdaq 2,870.99 +33.46 1.18%
Ticker Volume Price Price Delta
STOXX 50 2,160.31 +12.39 0.58%
FTSE 100 5,391.14 +34.80 0.65%
DAX 6,396.84 +73.65 1.16%
Ticker Volume Price Price Delta
Nikkei 8,571.90 -85.18 -0.98%
TOPIX 718.22 -8.81 -1.21%
Hang Seng 18,653.70 -401.79 -2.11%
Gold 1,548.10 -0.19%
EUR-USD 1.2465 -0.3033%
Nasdaq 2,870.99 +1.18%
DJIA 12,580.70 +1.01%
S&P 500 1,332.42 +1.11%
FTSE 100 5,391.14 +0.65%
STOXX 50 2,160.31 +0.58%
DAX 6,396.84 +1.16%
Oil (WTI) 90.33 -0.47%
U.S. 10-year 1.719% -0.019
BAC:US 7.44 +4.06%
FB:US 28.84 -9.62%
  • Exchange: -
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

Genzyme Corp

GENZ:US

Acquired

Genzyme Corp (GENZ:US) was acquired by SAN:FP


Company Profile

Genzyme Corporation provides biotechnology products development. The Company focuses on developing therapeutics for rare disorders, renal diseases, orthopaedics, cancer, transplant and immune disease, and diagnostic and predictive testing. Genzyme serves healthcare provider throughout worldwide.

Advertisement